Original Article
Copyright ©2011 Baishideng Publishing Group Co.
World J Gastroenterol. May 7, 2011; 17(17): 2181-2190
Published online May 7, 2011. doi: 10.3748/wjg.v17.i17.2181
Table 1 Clinical characteristics of the patient groups n (%)
IBD
Controls
UCCDNon-IBDHC
No. of patients84264340
Female (%)48 (57.1)13 (50)23 (53.4)18 (45)
Age (mean ± SD, yr)38 ± 12.642.6 ± 15.549.8 ± 18.330.8 ± 5.4
Location of disease
Ulcerative proctitis, E116 (19)
Left-sided colitis, E216 (19)
Extensive colitis, E352 (62)
Small bowel, L14 (15.5)
Colon, L215 (57.6)
Ileocolonic, L37 (26.9)
Disease behavior
Inflammatory25 (96.1)
Stenosing1 (3.9)
Penetrating0
Index disease0123 ≤ 8≥ 9
Endoscopic Mayo score8 (9.5)40 (47.6)25 (29.7)11(13.2)
Histopathological score8 (9.5)35 (41.6)32 (38.1)9 (10.7)
Harvey-Bradshaw Index22 (84.6)4 (15.4)
SES-CD24 (92.3)2 (7.7)
Medication at endoscopy
No medication14 (16.6)5 (19.2)
Topical 5-ASA16 (19)2 (7.7)
Systemic 5-ASA24 (28.5)7 (26.9)
Systemic steroids10 (11.9)3 (11.6)
5-ASA + steroids13 (15.5)0
5-ASA + azathioprine7 (8.5)4 (15.4)
Azathioprine05 (19.2)
Table 2 Sensitivity, specificity and cut-off values for sST2 in ulcerative colitis patients compared to other groups
Inactive UC
Active UC
Cut-off value (pg/mL)Sensitivity (%)Specificity (%)AUC (95% CI)Cut-off value (pg/mL)Sensitivity (%)Specificity (%)AUC (95% CI)
HC33.0854.2952.080.58 (0.46 -0.71)64.2594.2991.670.98 (0.95-1.00)b
Non IBD42.6760.9864.580.58 (0.45-0.70)76.2980.4983.330.90 (0.84-0.97)b
iUC----74.8783.3383.330.92 (0.86-0.97)b
Table 3 Correlation data of endoscopic and histopathological scores with serum sST2, interleukin-33, interleukin-6, tumor necrosis factor-α levels and total intestinal ST2
Disease activity indexEndoscopic scoreHistopathological score
sST2 (pg/mL)
r0.76240.6762
P-value< 0.0001< 0.0001
IL-33 (pg/mL)
r0.28690.1687
P-value0.01460.1657
IL-6 (pg/mL)
r0.23150.0888
P-value0.06760.2855
TNF-α (pg/mL)
r0.69610.6112
P-value< 0.0001< 0.0001
Intestinal ST2 (pg/mL per mg protein)
r0.62670.6034
P-value< 0.0001< 0.0001
Table 4 Baseline serum sST2 levels according to clinical characteristics of patients
Serum sST2 (pg/mL), median (Percentiles 25th-75th)
UCNon-IBDHC
Gender
Female55.5 (29.3-150.1)43.9 (22.1-73.1)29.4 (17.0-40.3)
Male99.7 (34.0-216.4)59.7 (35.6-74.9)36.2 (27.0-53.2)
Age (yr)
18-24190.8 (52.6-489.6)63.2 (31.7-74.9)29.0 (17.0-45.0)
25-3466.2 (30.4-313.3)46.3 (18.5-116.6)32.4 (16.9-40.8)
35-44125.4 (37.0-182.9)48.1 (32.2-67.8)44.3 (27.9-59.6)
45-5448.2 (24.9-116.4)43.6 (26.0-72.4)51.0 (35.7-65.0)
≥ 5551.3 (19.9-90.5)53.0 (25.9-78.8)0
Location of disease
Ulcerative proctitis, E156.5 (22.4-141.6)
Left-sided colitis, E235.8 (19.4-66.2)
Extensive colitis, E3110.2 (34.0-345.8)a
Medication at endoscopy
No medication36.4 (19.6-105.6)
Topical 5-ASA39.7 (20.4-75.7)
Systemic 5-ASA59.0 (23.6-141.7)
Systemic steroids242.4 (124.9-349.1)a
5-ASA + steroids125.4 (50.0-417.9)
5-ASA + azathioprine41.1 (68.9-109.0)
Azathioprine0